| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S11307-017-1132-4 |
| P698 | PubMed publication ID | 29027074 |
| P50 | author | Nicolas Aide | Q53064031 |
| P2093 | author name string | Jean-Jacques Parienti | |
| Alison C Johnson | |||
| Alain Batalla | |||
| Arthur Letellier | |||
| Jean-François Savigny | |||
| Nicolas How Kit | |||
| P2860 | cites work | Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach | Q29614698 |
| Alpha emitter radium-223 and survival in metastatic prostate cancer | Q29617472 | ||
| MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates | Q30558459 | ||
| Statistical issues in analysis of diagnostic imaging experiments with multiple observations per patient | Q34446769 | ||
| 18F-fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with 223Ra-chloride (Alpharadin) | Q35335407 | ||
| Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer. | Q35808384 | ||
| A bone marrow toxicity model for ²²³Ra alpha-emitter radiopharmaceutical therapy. | Q36235572 | ||
| Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamide | Q36670075 | ||
| Determination of Skeletal Tumor Burden on 18F-Fluoride PET/CT. | Q37261280 | ||
| 3D skeletal uptake of 18F sodium fluoride in PET/CT images is associated with overall survival in patients with prostate cancer | Q37647591 | ||
| Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial | Q38212374 | ||
| Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments | Q38737416 | ||
| The Association Between Liver and Tumor [18F]FDG Uptake in Patients with Diffuse Large B Cell Lymphoma During Chemotherapy. | Q38763481 | ||
| Repeatability of SUV in Oncologic 18F-FDG PET. | Q38945159 | ||
| Therapy assessment in prostate cancer using choline and PSMA PET/CT. | Q39328036 | ||
| Therapy assessment of bone metastatic disease in the era of 223radium. | Q39342954 | ||
| Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study | Q39970827 | ||
| (18)F-NaF PET/CT: EANM procedure guidelines for bone imaging. | Q40707077 | ||
| PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer | Q42328242 | ||
| Analytic Validation of the Automated Bone Scan Index as an Imaging Biomarker to Standardize Quantitative Changes in Bone Scans of Patients with Metastatic Prostate Cancer | Q42376623 | ||
| Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer | Q46123769 | ||
| Repeatability of 18F-FDG uptake measurements in tumors: a metaanalysis | Q47913737 | ||
| [68Ga]PSMA-HBED-CC Uptake in Osteolytic, Osteoblastic, and Bone Marrow Metastases of Prostate Cancer Patients | Q48127957 | ||
| The potential of 223Ra and 18F-fluoride imaging to predict bone lesion response to treatment with 223Ra-dichloride in castration-resistant prostate cancer | Q48282284 | ||
| Dosimetry of bone metastases in targeted radionuclide therapy with alpha-emitting (223)Ra-dichloride. | Q48757757 | ||
| Metabolic Tumor Burden Assessed by Dual Time Point [18F]FDG PET/CT in Locally Advanced Breast Cancer: Relation with Tumor Biology. | Q51008272 | ||
| Assessment of porcine bone metabolism by dynamic. | Q52059573 | ||
| Factors affecting (223)Ra therapy: clinical experience after 532 cycles from a single institution. | Q53328506 | ||
| Prognostic Factors in Patients Treated with 223Ra: The Role of Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT in Predicting Overall Survival. | Q53470024 | ||
| The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. | Q53553364 | ||
| Repeatability of Quantitative 18F-NaF PET: A Multicenter Study. | Q53776714 | ||
| Prospective evaluation of (99m)Tc MDP scintigraphy, (18)F NaF PET/CT, and (18)F FDG PET/CT for detection of skeletal metastases | Q83821456 | ||
| Quantitative imaging of 223Ra-chloride (Alpharadin) for targeted alpha-emitting radionuclide therapy of bone metastases | Q83924682 | ||
| ¹⁸F-Fluoride PET/CT is highly effective for excluding bone metastases even in patients with equivocal bone scintigraphy | Q84937940 | ||
| P577 | publication date | 2017-10-12 | |
| P1433 | published in | Molecular Imaging and Biology | Q6895951 |
| P1476 | title | Uptake of Radium-223 Dichloride and Early [(18)F]NaF PET Response Are Driven by Baseline [(18)F]NaF Parameters: a Pilot Study in Castration-Resistant Prostate Cancer Patients |
| Q90260579 | PET/CT-Based Response Evaluation in Cancer-a Systematic Review of Design Issues |
| Q64118574 | Ra-dichloride therapy of bone metastasis: optimization of SPECT images for quantification |
| Q57100038 | The Potential Use of 11C-Choline Positron Emission Tomography/Computed Tomography to Monitor the Treatment Effects of Radium-223 in a Patient with Prostate Cancer |
Search more.